Table 2.
Patient Identification |
Sex | Age, y |
Race/E thnicit y |
Clinical Presentation |
Genetic Diagnosis | Gene Symbol |
Sequence Variant, RSID, and ExAC Frequency |
Clinical Implications of Genetic Information |
---|---|---|---|---|---|---|---|---|
Genetic diagnoses that confirmed the clinical diagnosis and their potential implications on clinical care | ||||||||
| ||||||||
K008 | Female | 28 | White | ESRD of unknown cause, has undergone kidney transplantation, son has Alport syndrome | X-linked Alport syndrome (OMIM 301050) | COL4A5 | NM_000495:c.G3310T:p.G1104C† | Clarification of mode of inheritance; screening family members |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K009 | Male | 26 | White | Biopsy-proven Alport syndrome, negative FHx | X-linked Alport syndrome (OMIM 301050) | COL4A5 | NM_000495:c.G2731A:p.G911R | Clarification of mode of inheritance; screening family members |
RSID: rs281874704 | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K024 | Female | 31 | White | Biopsy-proven Alport syndrome, negative FHx | X-linked Alport syndrome (OMIM 301050) | COL4A5 | NM_000495:c.G5042A:p.C1681Y† | Clarification of mode of inheritance; screening family members |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K079 | Male | 22 | White | Biopsy-proven Alport syndrome, positive FHx | X-linked Alport syndrome (OMIM 301050) | COL4A5 | NM_000495:c.G2474A:p.G825E† | Clarification of mode of inheritance; screening family members |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K054 | Female | 31 | White | Nail–patella syndrome with biopsy-proven FSGS | Nail–patella syndrome (OMIM 161200) | LMX1B | NM_001174146: 775_776del: p.S259Cfs*38 | Do not consider immunosuppression; refer for transplant |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K015 | Male | 37 | Asian | Fabry disease by biopsy and enzyme activity, ESRD | Fabry disease(OMIM 301500) | GLA | NM_000169:c.A886G:p.M296V | Screening family members; continue enzyme therapy |
RSID: rs104894830 | ||||||||
ExAC frequency: 4 × 10−6 | ||||||||
Genetic diagnoses that provided new information and their potential implications on clinical care | ||||||||
| ||||||||
K030 | Male | 19 | African American | CKD of unknown cause with bilateral renal hypoplasia, hypogonadism; history of repaired atrial septal defect; offspring of healthy parents | CHARGE syndrome (OMIM 214800) | CHD7 | NM_017780:c.G8554A:p.D2852N† | Screening for hearing and visual loss, cranial nerve dysfunction, and learning disability; caution during anesthesia because of upper airway maldevelopment |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
KGY1 | Male | 35 | White | Familial proteinuric CKD of unknown cause, inconclusive results on biopsies at age 6 and 12 y, brother with proteinuria (never had biopsy) | Dent disease 1 (OMIM 300009) | CLCN5 | NM_000084:c.2057delG:p.S686Tfs*5 | Therapy with thiazide diuretics and citrates; no posttransplant recurrence expected; brother screened and diagnosed with Dent disease 1 |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K014 | Female | 22 | White | ESRD of unknown cause, has undergone kidney transplantation, positive FHx of microhematuria on father’s side | Autosomal recessive Alport syndrome (OMIM 203780) | COL4A3 |
NM_000091:c.G1558C:p.G520R
|
Posttransplant recurrence unlikely; compound heterozygosity confirmed by testing allele transmission in offspring; immunosuppressive therapy not indicated; family counseling |
NM_000091:c.T4421C:p.L1474P
| ||||||||
| ||||||||
K078 | Female | 28 | White | FSGS by biopsy, has had kidney transplantation, sibling died at age 17 y with anasarca, FHx of hematuria | Autosomal recessive Alport syndrome (OMIM 203780) | COL4A4 |
NM_000092:c.G4288A:p.G1430R
|
Compound heterozygosity confirmed by testing allele transmission in offspring; immunosuppressive therapy not indicated; family counseling; patient opted to pursue pregnancy after genetic diagnosis clarified recessive inheritance |
NM_000092:c.213_239del:p.P72_G80delPQGPIGPLG
| ||||||||
| ||||||||
K058 | Male | 28 | White | FSGS by biopsy, undergoing kidney transplant evaluation positive FHx for nephropathy | Autosomal dominant Alport syndrome (OMIM 104200) | COL4A4 | NM_000092:c.G1145C:p.G382A† | Immunosuppressive therapy not indicated; family screening for donor evaluation; referred for gene therapy trial |
RSID: rs751952236 | ||||||||
ExAC frequency: 4 × 10−5 | ||||||||
| ||||||||
K028 | Female | 57 | White | mild CKD of unknown cause with hematuria. TBMD diagnosed as a child (self-reported), | X-linked Alport syndrome (OMIM 301050) | COL4A5 | NM_000495:c.G5030A:p.R1677Q | Auditory and ophthalmology screening; referred for clinical trial (NCT02855268) |
RSID: rs104886308 | ||||||||
ExAC frequency: 2.3 × 10−5 | ||||||||
| ||||||||
K064 | Male | 48 | White | CKD of unknown cause with congenital small left kidney, diabetes, no prior kidney biopsy. | HNF1B-associated disease‡ (OMIM 137920) | HNF1B | NM_000458:c.C742T:p.Q248X | Insulin therapy; screening for hyperuricemia, hypomagnesemia, and hypoparathyroidism; family screening and counseling |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K065 | Male | 20 | White | Presented with hypertension and hypokalemia at age 13 y | Liddle syndrome (OMIM 177200) | SCNN1G | NM_001039:c.C1874G:p.P625R† | Treat with amiloride |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K027 | Female | 44 | White | Gitelman syndrome, type 2 diabetes | Gitelman syndrome (OMIM 263800) | SLC12A3 |
NM_000339: A2899G:p.R967G
|
– |
NM_000339:c.2986_2987insGCTC:p.Y999Afs*50
| ||||||||
| ||||||||
K006 | Female | 42 | White | Biopsy-proven FSGS, mother with ESRD has undergone kidney transplantation | FSGS type 2(OMIM 603965) | TRPC6 | TRPC6:NM_004621: A434G:p.H145R† | Affected mother tested positive for mutation; immunosuppression is not indicated |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K007 | Male | 55 | White | CKD with chronic tubulointerstitial nephropathy on biopsy, undergoing kidney transplant evaluation, Strong FHx for dominant transmission of CKD/ESRD | Autosomal dominant medullary cystic kidney disease type 2(OMIM 603860) | UMOD | NM_001008389:c.G317A:p.C106F† | Family screening and counseling; monitor uric acid levels |
RSID: rs398123697 | ||||||||
ExAC frequency: 3.7 × 10−5 | ||||||||
| ||||||||
K016 | Male | 21 | White/Hispanic | Gout and CKD of unknown cause, no biopsy; positive FHx for dominant transmission of ESRD/gout | Autosomal dominant medullary cystic kidney disease type 2 (OMIM 603860) | UMOD | NM_001008389:c.G774C:p.W258C† | Family screening and counseling; monitor uric acid levels |
RSID: NA | ||||||||
ExAC frequency: 0 | ||||||||
| ||||||||
K043 | Female | 45 | Asian | CKD with chronic tubulointerstitial nephropathy by biopsy, positive FHx for dominant transmission of CKD and gout | Autosomal dominant medullary cystic kidney disease type 2 (OMIM 603860) | UMOD | NM_001008389:c.T638A:p.M213K† | Family screening and counseling; monitor uric acid levels |
RSID: NA | ||||||||
ExAC frequency: 0 |
CHARGE = coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities; CKD = chronic kidney disease; ESRD = end-stage renal disease; ExAC = Exome Aggregation Consortium; FHx = family history; FSGS = focal segmental glomerulosclerosis; NA = not applicable ; OMIM = Online Mendelian Inheritance in Man; RSID = Reference Single Nucleotide Polymorphism identification number ; TBMD = thin basement membrane disease.
Likely a pathogenic mutation.
Also known as renal cysts and diabetes syndrome or maturity-onset diabetes of the young type 5.